Oncologists are still in the dark about plans to improve PBS access to checkpoint inhibitors following a special PBAC meeting in August to consider the issues around listing of PD-1 and PD-L1 drugs for multiple cancer indications. Support for the concept of multi-tumour listings has grown since last year’s landmark decision by the US FDA ...
“Disappointing” verdict on PBS plans for pan-tumour listings
By Mardi Chapman
10 Oct 2018